Innovations and Challenges in Renal Cancer
Second Cambridge Conference - April 2006
This program was based on a multidisciplinary conference of leaders in the field. The focus of the program was to address critical issues in the field and develop an educational proceedings summarizing recent progress and outlining priorities for research and clinical care.
The program was directed by Michael B Atkins, MD, Beth Israel Deaconess Medical Center/Dana Farber/Harvard Cancer Center.
The proceedings of the meeting were published as a peer-reviewed supplement to the journal Clinical Cancer Research (CCR, Vol 13, No 2, January 15, 2007.), including a CME activity based on the consensus summary. Links to the table of contents, consensus summary statement and journal website are below. The CME activity is no longer active.
Statement of Need
Our understanding of renal cancer biology has accelerated over the past two years, fueled by new information on existing therapies, the application of new technologies and the clinical evaluation of a variety of novel agents. Together, these advances are contributing to a wave of innovations in detecting, evaluating and treating renal cancer and its complications. Several important new technologies and therapies are currently in development, and a great deal of new clinical information is becoming available, with potentially significant implications for disease management.
Educational Grant Support
Supported by educational grants provided by Bayer Pharmaceuticals, Inc./Onyx Pharmaceuticals, Chiron Corporation, Genentech, Pfizer, Inc., Schering Plough, Wyeth Pharmaceuticals, and the Kidney Cancer Foundation.
Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.
